FDA/CDC

FDA approves rifamycin for treatment of traveler’s diarrhea


 

The Food and Drug Administration has approved rifamycin (Aemcolo) for the treatment of traveler’s diarrhea caused by noninvasive strains of Escherichia coli.

FDA icon

FDA approval was based on results of three clinical trials. The efficacy of rifamycin was shown in a trial of 264 adults with traveler’s diarrhea in Guatemala and Mexico. Compared with placebo, rifamycin significantly reduced symptoms of the condition. The safety of rifamycin was illustrated in a pair of studies including 619 adults with traveler’s diarrhea who took rifamycin orally for 3-4 days. The most common adverse events were headache and constipation.

Traveler’s diarrhea is the most common travel-related illness, affecting 10%-40% of travelers. It can be caused by a multitude of pathogens, but bacteria from food or water is the most common source. High-risk areas include much of Asia, the Middle East, Mexico, Central and South America, and Africa.

Rifamycin was not effective in patients with diarrhea complicated by fever and/or bloody stool or in diarrhea caused by a pathogen other than E. coli.

“Travelers’ diarrhea affects millions of people each year, and having treatment options for this condition can help reduce symptoms of the condition,” Edward Cox, MD, MPH, director of the Office of Antimicrobial Products in the FDA’s Center for Drug Evaluation and Research, said in the press release.

Find the full press release on the FDA website.

Recommended Reading

FDA authorizes emergency use of rapid fingerstick test for Ebola
MDedge Infectious Disease
Good news, bad news about HCV in kidney disease
MDedge Infectious Disease
How to slash colorectal surgery infection rates
MDedge Infectious Disease
Chronic liver disease independently linked to increased risk of falls
MDedge Infectious Disease
Children are vulnerable to diseases emerging because of climate change
MDedge Infectious Disease
More acute flaccid myelitis cases confirmed by CDC
MDedge Infectious Disease
High rates of HCV treatment completion seen in people who inject drugs
MDedge Infectious Disease
HCV antibodies linked to poorer cardiac outcomes in ACHD patients
MDedge Infectious Disease
Consider omitting CSF testing in older, low-risk febrile infants
MDedge Infectious Disease
Experts advise risk stratification for newborn early-onset sepsis
MDedge Infectious Disease